Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
The recent advances in EGFR M+ NSCLC and the availability of different treatment options, including treatment novelities such as osimertinib and afatinib, are summarized in this review.
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Subjects: | |
| Online Access: | https://onco-hema.healthbooktimes.org/article/24422-critical-review-of-egfr-mutated-nsclc-what-we-do-and-do-not-know |
| _version_ | 1798014859019812864 |
|---|---|
| author | Alexander Meisel |
| author_facet | Alexander Meisel |
| author_sort | Alexander Meisel |
| collection | DOAJ |
| description | The recent advances in EGFR M+ NSCLC and the availability of different treatment options, including treatment novelities such as osimertinib and afatinib, are summarized in this review. |
| first_indexed | 2024-04-11T15:23:49Z |
| format | Article |
| id | doaj.art-a77ba886bf9745d29dbd9530d9849cf0 |
| institution | Directory Open Access Journal |
| issn | 2673-2092 2673-2106 |
| language | English |
| last_indexed | 2024-04-11T15:23:49Z |
| publishDate | 2020-03-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj.art-a77ba886bf9745d29dbd9530d9849cf02022-12-22T04:16:18ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062020-03-0113203510.36000/hbT.OH.2020.03.012Critical Review of EGFR-Mutated NSCLC What We Do and Do Not KnowAlexander Meisel0https://orcid.org/0000-0003-2422-1281Department of Nuclear Medicine, University Hospital of Zurich; Institute of Pharmaceutical Sciences, ETH ZurichThe recent advances in EGFR M+ NSCLC and the availability of different treatment options, including treatment novelities such as osimertinib and afatinib, are summarized in this review.https://onco-hema.healthbooktimes.org/article/24422-critical-review-of-egfr-mutated-nsclc-what-we-do-and-do-not-knowafatinibtkisegfr-mutationnsclc |
| spellingShingle | Alexander Meisel Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know healthbook TIMES. Oncology Hematology afatinib tkis egfr-mutation nsclc |
| title | Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know |
| title_full | Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know |
| title_fullStr | Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know |
| title_full_unstemmed | Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know |
| title_short | Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know |
| title_sort | critical review of egfr mutated nsclc what we do and do not know |
| topic | afatinib tkis egfr-mutation nsclc |
| url | https://onco-hema.healthbooktimes.org/article/24422-critical-review-of-egfr-mutated-nsclc-what-we-do-and-do-not-know |
| work_keys_str_mv | AT alexandermeisel criticalreviewofegfrmutatednsclcwhatwedoanddonotknow |